Annual Reports in Medicinal Chemistry (eBook, PDF)

• Format: PDF

Produktbeschreibung

Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry together with an emphasis on emerging topics in the biological sciences, which are expected to provide the basis for entirely new future therapies.

• Covers findings related to cardiovascular, inflammation, and pulmonary diseases
• Examines issues in oncology, from mTor inhibitors to drug targets
• Incorporates up-to-date information on drug design and discovery, including delivery to market

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Science & Techn.
• Seitenzahl: 648
• Erscheinungstermin: 25. November 2010
• Englisch
• ISBN-13: 9780123809032
• Artikelnr.: 38016883

Inhaltsangabe

Section I: Central Nervous System Diseases - ROBICHAUD

1. Voltage-Gated Calcium Channel Antagonists for the Central Nervous System


James C. Barrow and Joseph L. Duffy


2. Recent Developments in Glycine Transporter-1 Inhibitors


Christopher L. Cioffi, Shuang Liu and Mark A.Wolf


3. Modulators of Transient Receptor Potential Ion Channels


Rajagopal Bakthavatchalam and S. David Kimball


4. Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships


Christopher L. Shaffer

Section II: Cardiovascular and Metabolic Diseases - STAMFORD


5. High Affinity Niacin Receptor GPR109A Agonists


Hong C. Shen and Steven L. Colletti


6. Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors


Matthew P. Bourbeau, John G. Allen, and Wei Gu


7. Enzymatic Targets in the Triglyceride Synthesis Pathway


Dmitry O. Koltun and Jeff Zablocki


8. Inhibitors of HIF Prolyl Hydroxylases


Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan

Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein


9. Opioid Receptor Antagonists for Gastrointestinal Dysfunction


R. William Hipkin and Roland E. Dolle


10. CFTR Modulators for the Treatment of Cystic Fibrosis


Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis


11. Targeting B-cells in inflammatory disease


Kevin S. Currie


12. Modulators of Toll-Like Receptor (TLR) Signaling


Mark Spyvee, Lynn Hawkins, and Sally Ishizaka

Section IV: Oncology - McAlpine


13. Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)


Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo


14. Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology


Philip Jones


15. Epigenetic Targets and Cancer Drug Discovery


Patrick M. Woster, Ph.D

Section V: Infectious Diseases - Primeau


16. HIV-1 Integrase Strand Transfer Inhibitors


Brian A. Johns


17. Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites


Robert T. Jacobs and Charles Ding


18. Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis


Vincent Gerusz

Section VI: Topics in Biology - LOWE


19. Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer's Disease


Dr. Robert B. Nelson


20. Targeting Methyl Lysine


Stephen V. Frye, Tom Heightman and Jian Jin


21. Chemical Proteomic Technologies for Drug Target Identification


Kieran F. Geoghegan and Douglas S. Johnson


22. NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development


Raj N. Misra

Section VII: Topics in Drug Design and Discovery - DESAI


23. Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks


Martin P. Edwards and David A. Price


24. Reducing the Risk of Drug Attrition Associated with Physicochemical Properties


Paul D. Leeson and James R. Empfield


25. Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update


Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski


26. The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties


Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman


27. Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property


Charles J. Andres, Jr. and Richard L. Treanor

Section VIII: Trends and Pers